Argentina vs Iraq: Average cost of multi drug-resistant tuberculosis treatment
Argentina
1,547 constant 2022 US$
in 2024
Iraq
1,500 constant 2022 US$
in 2024
Argentina rank
31st
Iraq rank
34th
Average cost of multi drug-resistant tuberculosis treatment over time
- Argentina
- Iraq
How they compare
Argentina currently reports 1,547 constant 2022 US$ against 1,500 constant 2022 US$ in Iraq, a difference of 47 constant 2022 US$.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 31st and Iraq ranks 34th of 92 countries.
Iraq has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,035 constant 2022 US$ | 4,000 constant 2022 US$ | 965.33 constant 2022 US$ | Iraq |
| 2020s | 1,334 constant 2022 US$ | 2,300 constant 2022 US$ | 965.6 constant 2022 US$ | Iraq |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Argentina or Iraq?
- Argentina, at 1,547 constant 2022 US$ against 1,500 constant 2022 US$ in Iraq as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Argentina and Iraq?
- 47 constant 2022 US$, with Argentina ahead.
- How many years of comparable data are there for Argentina and Iraq?
- 8 years are reported by both, from 2017 to 2024.
- How do Argentina and Iraq rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Argentina ranks 31st and Iraq ranks 34th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.